文献速递基础与转化研究临床试验与 GCP

CD19 CAR-T细胞疗法治疗自身免疫性溶血性贫血

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.
PubMed 文献 · N Engl J Med · 2026-01-01

这项研究纳入接受同情用药项目和1期试验的原发性多重难治性自身免疫性溶血性贫血患者,每人接受单次自体CD19 CAR-T细胞输注,主要评估安全性,次要评估疗效和药代动力学特征。11例患者全部获得完全缓解,中位完全缓解时间45天,中位无药缓解持续时间11.5个月,细胞因子释放综合征多为1-2级。

要点

  • 11例多重难治性自身免疫性溶血性贫血患者接受单次CD19 CAR-T细胞输注后全部获得完全缓解。
  • 中位完全缓解时间45天,中位无药缓解持续时间11.5个月,中位随访12.2个月。
  • 细胞因子释放综合征1-2级发生于9例,1级免疫效应细胞相关神经毒性综合征发生于1例。

核心结论

  • CD19 CAR-T细胞疗法在多重难治性自身免疫性溶血性贫血患者中具有预期的毒性作用,并实现了持续缓解。

研究设计与样本

  • 研究纳入同情用药项目和1期试验中的原发性多重难治性自身免疫性溶血性贫血患者,每例接受单次自体CD19 CAR-T细胞输注。
  • 共11例患者接受CD19 CAR-T细胞治疗,其中同情用药项目5例,1期研究6例。
  • 主要目标为评估安全性,包括不良事件的发生率、特征和严重程度,涵盖细胞因子释放综合征和免疫效应细胞相关神经毒性综合征;次要目标包括疗效和药代动力学特征。
  • 完全缓解定义为症状消退、血红蛋白水平升高和溶血标志物正常化。
  • 中位随访12.2个月(范围7.3至21.9)。

主要发现

  • 所有患者均获得完全缓解,中位完全缓解时间为45天(范围21至153)。
  • 中位无药缓解持续时间为11.5个月(范围6.8至21.0)。
  • 9例患者发生1级或2级细胞因子释放综合征,1例患者发生1级免疫效应细胞相关神经毒性综合征。
  • 7例患者共发生15次感染,无4级或以上感染;1例患者发生3级免疫效应细胞相关血液毒性。
  • 在连续样本的多组学评估中,无药缓解患者重建的B细胞群以初始B细胞为主,HLA-DRB5+ B细胞、CD4+ T细胞和表达B细胞成熟抗原的长寿命浆细胞之间的交互作用促成了复发特异性B细胞龛。

关键数值与推荐

  • 完全缓解定义为症状消退、血红蛋白水平升高和溶血标志物正常化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is defined by a lack of response to at least three lines of therapy. CD19-directed chimeric antigen receptor (CAR) T-cell therapy results in profound B-cell depletion and may be a useful approach to achieving drug-free remission in multirefractory AIHA. METHODS: We enrolled patients from a compassionate-use program and those from a phase 1 study who had primary multirefractory AIHA. Each patient received a single infusion of autologous CD19 CAR T cells. The primary objective was to assess the safety profile - the incidence, characteristics, and severity of adverse events, including cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome. Secondary objectives included efficacy and pharmacokinetic features. A complete response was defined by resolution of symptoms, an increased hemoglobin level, and normalization of hemolysis markers. B-cell reconstitution and the origin of relapse were analyzed with flow cytometry, single-cell RNA sequencing, and paired B-cell receptor sequencing. RESULTS: CD19 CAR T cells were administered to 11 patients - 5 in the compassionate-use program and 6 in the phase 1 study. The median follow-up was 12.2 months (range, 7.3 to 21.9). All patients had a complete response; the median time to a complete response was 45 days (range, 21 to 153). The median duration of drug-free remission was 11.5 months (range, 6.8 to 21.0). Cytokine-release syndrome of grade 1 or 2 in severity occurred in 9 patients, and immune effector cell-associated neurotoxicity syndrome of grade 1 occurred in 1 patient. A total of 15 infections occurred among 7 patients, with no infections of grade 4 or higher. One patient had immune effector cell-associated hematotoxicity of grade 3. In multi-omics assessments of sequential samples, naive B cells were predominant in the reconstituted B-cell population in patients with drug-free remission, and crosstalk between HLA-DRB5+ B cells, CD4+ T cells, and B-cell maturation antigen-expressing long-lived plasma cells contributed to a relapse-specific B-cell niche. CONCLUSIONS: CD19 CAR T-cell therapy had expected toxic effects and resulted in sustained remission in patients with multirefractory AIHA. (Funded by the National Key Research and Development Program of China and others; ClinicalTrials.gov number, NCT06231368.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Li R, Pan H, Zhang L, et al. CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. N Engl J Med. 2026. PMID: 41534043. doi:10.1056/NEJMoa2509820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。